Studies have revealed that ATRX mutations in grade II–III astrocytomas, oligoastrocytomas, and secondary GBMs often cooccur with IDH1 mutations and ALT activation.109 Additionally, the H3.3–ATRX–DAXX chromatin remodeling complex is frequently altered in pediatric GBMs, underscoring the role of ATRX in tumor development.101 These findings emphasize that ATRX mutations are key molecular markers for glioma classification and potential therapeutic intervention. The gene discussed is ATRX; the disease is neoplasm.